Altimmune Stock Price, News & Analysis

Altimmune, Inc. (Nasdaq: ALT) announced its participation in two upcoming investor conferences in June 2022. The events include the Jefferies 2022 Global Healthcare Conference on June 10 at 10:00 am ET and the JMP Securities Life Sciences Conference on June 16 at 9:00 am ET, both held in New York. Interested investors can access the webcast via the company’s website. Altimmune develops novel therapeutics for obesity and liver diseases.

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Samuel Klein will present at the 82^nd American Diabetes Association Scientific Sessions from June 3-7, 2022, in New Orleans, LA. He will discuss the results of a Phase 1 clinical trial for pemvidutide, a dual receptor agonist targeting obesity and NASH. The presentation is scheduled for June 6, 2022, at 4:30 pm CDT, highlighting pemvidutide's potential for significant weight loss without dose adjustments. Altimmune is committed to developing innovative peptide-based therapies for metabolic and liver diseases.

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris will present at the 5th Global NASH Congress in London on May 27, 2022. His presentation will focus on pemvidutide, a novel dual receptor agonist aimed at treating obesity and NASH. Dr. Harris will also moderate a panel on clinical endpoints in NASH trials. The event highlights Altimmune's commitment to developing innovative therapeutics in the weight loss and liver disease sectors.

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two investor conferences in May 2022. The H.C. Wainwright Global Investment Conference is set for May 24 at 7:00 am Eastern Time, available via webcast. The B. Riley Securities Institutional Investor Conference will take place on May 26 at 1:00 pm Pacific Time, featuring an in-person fireside chat. Altimmune focuses on developing novel therapeutics for obesity and liver diseases, including its lead candidate, pemvidutide (ALT-801).

Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q1 2022, showcasing ongoing clinical developments of pemvidutide, a dual receptor agonist for obesity. Notably, interim data from the Phase 2 MOMENTUM trial is expected in Q4 2022, with 10% weight loss observed after 12 weeks. However, revenue was minimal at $0.0 million, down from $0.8 million YoY, primarily due to halted projects. R&D expenses rose to $15.1 million, leading to a net loss of $19.4 million. The company holds $180 million in cash, offering a healthy runway for future trials.

Altimmune, a clinical-stage biopharmaceutical company, will announce its first quarter 2022 financial results on May 12, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its primary candidate being pemvidutide (ALT-801) for obesity and NASH treatment. Additionally, it is developing HepTcell™, aimed at treating chronic hepatitis B.

Altimmune, a clinical-stage biopharmaceutical company, announced the successful completion of enrollment in its 12-week Phase 1b trial of pemvidutide for non-alcoholic fatty liver disease (NAFLD) and the initiation of the 48-week Phase 2 MOMENTUM trial for obesity. The MOMENTUM trial aims to evaluate the safety and efficacy of pemvidutide, targeting approximately 320 non-diabetic subjects. Results from a prior Phase 1 trial indicated an average weight loss of 10.3%. Key data readouts are anticipated in Q3 and Q4 2022.

Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q4 and the full year of 2021, revealing a strong cash position of $190.3 million as of December 31, 2021. The company anticipates significant clinical data readouts over the next year, particularly from the pemvidutide (ALT-801) program, which showed promising results in weight loss and lipid reduction. The enrollment for the Phase 1b trial is over 90% complete, with data expected in Q3 2022. Revenue for Q4 2021 was $3.3 million, up from $2.3 million in Q4 2020, contributing to a net loss of $23.9 million for the quarter.

Altimmune, Inc. (Nasdaq: ALT) will report its fourth quarter and full year 2021 financial results on March 15, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), being developed for obesity and NASH. Additional developments include HepTcell™, an immunotherapeutic for chronic hepatitis B.